(MENAFN- Investor Brand Network) Cybin (NEO: CYBN)
(NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has been granted two patents by the United States Patent and Trademark Office; the patents offer protection for the company's deuterated N, N-dimethyltryptamine (“DMT”) program, including deuterated analogs of DMT related to composition of matter, medical use and synthesis. According to the announcement, the company's intellectual portfolio (“IP”) now includes of 32 granted patents along with more than 170 pending applications. The granted patents include U.S. patent no. 11,771,681, which provides composition of matter protection for certain deuterated analogs of DMT, and U.S. patent no. 11,773,062, which provides protection for the medical use and the novel, efficient and scalable synthesis of certain analogs of DMT.
The company noted that both of its proprietary novel deuterated DMT compounds, CYB004 and SPL028, are in phase I clinical trials, with initial data demonstrating that IV CYB004 and SPL028 elicit a psychedelic experience of less than one hour and are well tolerated. The company anticipates topline data readouts from both studies in Q4 2023.“Following Cybin's recent acquisition of Small Pharma Inc., our development programs are protected by 32 granted patents and over 170 pending applications, establishing our leadership position in developing novel tryptamine-based therapeutics in a key market,” said Cybin CEO Doug Drysdale in the press release.“This multilayered and robust IP protection includes composition of matter, medical use, synthesis and drug-product protection, providing us with the latitude to advance our deuterated programs with confidence.”
To view the full press release, visit
About Cybin Inc.
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental-health conditions. Cybin's goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For more information, visit the company's website at
.
NOTE TO INVESTORS:
The latest news and updates relating to CYBN are available in the company's newsroom at
About InvestorWire
InvestorWire
(“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:
InvestorWire
Los Angeles, CA
310.299.1717 Office
InvestorWire is powered by
IBN
MENAFN25102023000224011066ID1107304281
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.